Developing　photocatalytic　medicine　for　targeted　therapy　is　intriguing　but　still　remains　a　great　challenge.　Herein,　we　developed　a　nanophotosensitizer　(c-PDMS)　decorated　with　pancreatic　adenocarcinoma　(PAC)-targeting　DNA　aptamer　Xq-2D　(abbreviated　as　Xq-2D/c-PDMS)　for　enhanced　photo-dynamic-gas　synergistic　therapy　of　PAC.　c-PDMS　is　constructed　by　poly[2,6-(4,4-bis-(2-ethylhexyl)-4H-cyclopenta[2,1-b/3,4-b　＇]-dithiophene)-alt-4,7-(2,1,3-benzothiadiazole)]　(OSP)　integrated　into　dendritic　mesoporous　silica　(DMS)　through　a　one-step　method　and　further　loaded　with　the　CORM-401　prodrug　as　the　CO　donor.　Our　prepared　c-PDMS　can　produce　1O2　and　then　oxidate　the　CORM-401　prodrug　to　release　CO　gas　under　near　infrared　(NIR)　laser　irradiation.　After　being　decorated　by　Xq-2D　aptamer-HS　with　MAL-PEG-NHS,　the　resultant　Xq-2D/c-PDMS　showed　good　biocompatibility,　active　targeting,　and　high　cellular　uptake　ability　by　PAC　cells　compared　to　c-PDMS　alone,　which　led　to　an　efficient　killing　effect　to　fight　against　PAC　cancer　cells　through　1O2　oxidization　and　CO-mediated　mitochondrial　respiration　inhibition.　Furthermore,　the　excellent　antitumor　efficiency　of　Xq-2D/c-PDMS　in　vivo　with　minimized　side　effects　was　clarified　by　the　analysis　of　tumor　volume　and　weight,　H&E　staining　of　tumors,　biochemical　indexes,　and　weight　loss　after　NIR　laser　irradiation.　This　study　provides　an　efficient　synergistic　strategy　for　PAC　therapy.